Compare FENG & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FENG | BFRI |
|---|---|---|
| Founded | 1998 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.1M | 16.3M |
| IPO Year | 2011 | 2021 |
| Metric | FENG | BFRI |
|---|---|---|
| Price | $1.50 | $1.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.75 |
| AVG Volume (30 Days) | 2.8K | ★ 534.2K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.70 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,705,000.00 |
| Revenue This Year | N/A | $14.36 |
| Revenue Next Year | N/A | $16.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.75 |
| 52 Week Low | $1.39 | $0.57 |
| 52 Week High | $3.65 | $1.60 |
| Indicator | FENG | BFRI |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 74.99 |
| Support Level | $1.50 | $0.71 |
| Resistance Level | $1.80 | N/A |
| Average True Range (ATR) | 0.04 | 0.10 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 46.67 | 95.24 |
Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives all of its revenue from PRC.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.